Arginine auxotrophy due to the silencing of argininosuccinate synthetase 1 (ASS1) occurs in many 23 cancers, especially sarcomas. Arginine deiminase (ADI-PEG20) therapy exploits this metabolic 24 vulnerability by depleting extracellular arginine, causing arginine starvation. ASS1-negative cells 25 develop resistance to ADI-PEG20 through a metabolic adaptation that includes re-expressing 26 ASS1. As arginine-based multiagent therapies are being developed, further characterization of 27 the changes induced by arginine starvation is needed. In order to develop a systems-level 28 understanding of these changes, activity-based proteomic profiling (ABPP) and 29 phosphoproteomic profiling were performed before and after ADI-PEG20 treatment in ADI-30 PEG20-sensitive and resistant sarcoma cells. When integrated with previous metabolomic 31 profiling (Kremer et al, 2017a), this multi-omic analysis reveals that cellular response to arginine 32 starvation is mediated by adaptive ERK signaling, driving a Myc-Max transcriptional network.
Introduction

39
The loss of a functional urea cycle in many types of cancer results from the silencing of 40 argininosuccinate synthetase 1 (ASS1) expression (Kremer & Van Tine, 2017; Phillips et al, 2013;  7 141 SKLMS1 cells upregulate MAPK signaling and TCA proteins in response to ADI-PEG20, 142 but downregulate lipid metabolism 143 ABPP detected 1,912 proteins (ProteomeXchange repository PXD017043), and 144 substantial activity-based proteomic changes in both cell lines upon ADI-PEG20 treatment (Fig. 
145
3A). A clustered heatmap including all proteins that were differentially regulated (p-value 0.05) 146 reveals four distinct clusters, indicating that the proteomic response to ADI-PEG20 in each cell 147 line is highly individualized (Fig. 3B ).
148
In order to determine the biological pathways and functions of proteins regulated by ADI-9 MDH1 is upregulated by 1.6 fold, suggesting that OAA may be preferentially formed from malate 192 that has been exported to the cytoplasm (Fig. 4C ). Taken together, the results from the ABPP 193 analysis suggest that glutamine-based production of OAA and aspartate is driven by three 194 potential pathways: increased TCA cycle activity, anaplerotic carboxylation of pyruvate, and 195 inhibition of lipid metabolism that recycles cytoplasmic citrate back to the TCA cycle. The regulation of metabolic adaptation and reprogramming is highly pleiotropic, coordinating 200 regulation of kinases, transcription factors, and other proteins across multiple signaling pathways 201 (Brooks Robey et al, 2015) . Kinases are key transducers of signaling pathways, often clinically 10 In order to build a more complete picture of the regulatory networks involved in the response 217 to SKLMS1 and PCB-011 cells to arginine starvation, we performed X2K analysis on the ABPP 218 data (Chen et al, 2012) . X2K incorporates kinomic and other changes in protein expression to 219 infer regulatory networks. As X2K requires differentially expressed genes as input, all upregulated 220 proteins with a nominally significant p-value were included in the X2K analysis of each cell line.
221
Myc, and its activating heterodimeric partner Max, were the two most overrepresented 222 transcription factors in SKLMS1 cells upon ADI-PEG20 treatment, but were much less enriched 223 in PCB-011 cells (Fig. 6A ). Myc is stabilized in SKLMS1 cells upon ADI-PEG20 treatment and the 224 cMyc-Max heterodimerization inhibitor 10058-F4 blocks ADI-driven resistance consistent with this 225 regulatory model (Prudner et al, 2019b) . Network analysis indicated that Myc and Max are driven 226 by upstream activation of ERK1/2 (MAPK1/3, Fig. 6B ). ERK can phosphorylate and stabilize Myc 227 (Sears et al, 2000; Long et al, 2013) , supporting this regulatory model upon arginine starvation in 228 SKLMS1 cells. Taken together, the ABPP profiling indicates that adaptive changes in ERK1/2 229 upon ADI-PEG20 treatment stimulate a cMyc-Max transcriptional network in ADI-PEG20-230 sensitive SKLMS1 cells, but not in ADI-PEG20-resistant PCB-011 cells.
232
Discussion
233
Acquired resistance to anticancer therapy remains a major challenge and often occurs in the 234 absence of genetic mutations. Many cancers are arginine auxotrophic due to silencing of ASS1
In this study we employed phosphoproteomics and ABPP to characterize how the proteome 242 of SKLMS1 cells adapts upon arginine starvation. These methods proved to be complementary, 243 and by integrating these data with existing metabolomics data (Kremer et al, 2017a), we were 244 able to gain unique insights into the regulatory networks involved in ADI-PEG20 resistance in 245 ASS1-negative sarcoma. In line with existing literature, we identified adaptive kinomic changes in 246 ADI-PEG20-sensitive SKLMS1 cells, including upregulation of ERK1 and ERK2, which stimulate et al, 2008; Faddetta et al, 2018; Blachowicz et al, 2019) , parasites, and antibiotic resistance 264 (Akpunarlieva et al, 2017; Park et al, 2016) . However, utilization of integrative proteomic-265 metabolomic analysis has been limited with respect to modeling drug resistance and metabolism 12 exploration of ADI-PEG20 resistance elucidates numerous changes consistent with 268 metabolomics, and finds that these two -omics approaches provide complementary insight.
269
Importantly, 14% of the proteins detected by ABPP are annotated in UniProtKB as ATP 
282
For arginine starvation to become a mainstay of cancer treatment, a full understanding of the 283 metabolic and proteomic adaptation to ADI-PEG20 is needed. The metabolic changes that 284 promote escape from arginine starvation induce a new transcriptional profile as well as significant 285 alterations in protein regulation and activity. These changes that facilitate escape from arginine 286 deprivation also limit the metabolic flexibility of cells. It has yet to be determined if these metabolic 287 adaptations are permanent choices, but as long as the stress of extracellular arginine starvation 288 is present, the ability of a tumor to return to its metabolism of choice is limited. Understanding the 289 metabolic changes that occur upon treatment with metabolically targeted compounds in concert PCB-011 PCB-011 PCB-011 PCB-011 PCB-011 C  9  o  r  f  7  8  _  p  2  6  1  E  I  F  3  C  ;  E  I  F  3  C  L  _  p  3  9  L  M  N  A  _  p  3  9  0  R  B  M  1  5  _  p  6  5  6  U  S  P  4  7  _  p  8  1  2  B  C  L  A  F  1  _  p  5  2  9  M  A  P  4  _  p  2  9  7  C  L  I  P  1  _  p  2  0  4  M  A  P  1  S  _  p  7  3  3  F  L  N  A  _  p  1  0  8  4  M  A  C  F  1  _  p  2  4  3  3  T  R  A  M  1  _  p  2  7  9  L  I  G  1  _  p  7  6 H 
